Manchester Centre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre, Saint Mary's Hospital, Manchester, United Kingdom.
Manchester Centre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre, Saint Mary's Hospital, Manchester, United Kingdom; Manchester Royal Eye Hospital, Manchester Academic Health Science Centre, The University of Manchester, Central Manchester Foundation Trust, Manchester, United Kingdom.
Ophthalmology. 2014 Nov;121(11):2124-37.e1-2. doi: 10.1016/j.ophtha.2014.06.006. Epub 2014 Aug 19.
To assess the utility of integrating genomic data from next-generation sequencing and phenotypic data to enhance the diagnosis of bilateral congenital cataract (CC).
Evaluation of diagnostic technology.
Thirty-six individuals diagnosed with nonsyndromic or syndromic bilateral congenital cataract were selected for investigation through a single ophthalmic genetics clinic.
Participants underwent a detailed ophthalmic examination, accompanied by dysmorphology assessment where appropriate. Lenticular, ocular, and systemic phenotypes were recorded. Mutations were detected using a custom-designed target enrichment that permitted parallel analysis of 115 genes associated with CC by high-throughput, next-generation DNA sequencing (NGS). Thirty-six patients and a known positive control were tested. Suspected pathogenic variants were confirmed by bidirectional Sanger sequencing in relevant probands and other affected family members.
Molecular genetic results and details of clinical phenotypes were identified.
Next-generation DNA sequencing technologies are able to determine the precise genetic cause of CC in 75% of individuals, and 85% patients with nonsyndromic CC were found to have likely pathogenic mutations, all of which occurred in highly conserved domains known to be vital for normal protein function. The pick-up rate in patients with syndromic CC also was high, with 63% having potential disease-causing mutations.
This analysis demonstrates the clinical utility of this test, providing examples where it altered clinical management, directed care pathways, and enabled more accurate genetic counseling. This comprehensive screen will extend access to genetic testing and lead to improved diagnostic and management outcomes through a stratified medicine approach. Establishing more robust genotype-phenotype correlations will advance knowledge of cataract-forming mechanisms.
评估整合下一代测序的基因组数据和表型数据以增强双侧先天性白内障(CC)诊断的效用。
诊断技术评估。
通过单个眼科遗传学诊所选择了 36 名被诊断为非综合征或综合征性双侧先天性白内障的个体进行研究。
参与者接受了详细的眼科检查,并在适当的情况下进行了畸形评估。记录晶状体、眼部和全身表型。使用定制的靶向富集检测突变,该方法允许通过高通量、下一代 DNA 测序(NGS)平行分析 115 个与 CC 相关的基因。对 36 名患者和已知的阳性对照进行了测试。在相关先证者和其他受影响的家庭成员中通过双向 Sanger 测序确认可疑的致病性变异。
确定了分子遗传学结果和临床表型的详细信息。
下一代 DNA 测序技术能够确定 75%的 CC 个体的精确遗传原因,85%的非综合征性 CC 患者发现可能存在致病性突变,所有这些突变都发生在高度保守的区域,这些区域已知对正常蛋白质功能至关重要。综合征性 CC 患者的检出率也很高,有 63%的患者存在潜在的致病突变。
该分析证明了该测试的临床效用,提供了改变临床管理、指导护理途径并实现更准确遗传咨询的实例。这种全面筛查将扩大遗传检测的机会,并通过分层医学方法改善诊断和管理结果。建立更强大的基因型-表型相关性将推进白内障形成机制的知识。